Steve Charles, Philip J Rosenfeld, Steven Gayer. Show Affiliations »
Abstract
Mesh: See more » Angiogenesis Inhibitors/administration & dosageAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal, HumanizedAnticoagulants/administration & dosageBevacizumabEye Hemorrhage/etiologyEye Hemorrhage/prevention & controlHumansInjectionsOphthalmologic Surgical ProceduresRanibizumabRisk FactorsStroke/etiologyStroke/mortalityThromboembolism/etiologyThromboembolism/mortalityVascular Endothelial Growth Factor A/antagonists & inhibitorsVitrectomyVitreous BodyWarfarin/administration & dosageWithholding Treatment
Substances: See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAnticoagulantsVEGFA protein, humanVascular Endothelial Growth Factor ABevacizumabWarfarinRanibizumab
Year: 2007 PMID: 17891002 DOI: 10.1097/IAE.0b013e318154b9f2
Source DB: PubMed Journal: Retina ISSN: 0275-004X Impact factor: 4.256